These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 35331250)

  • 1. Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
    Zhang X; Yang Z; An Y; Liu Y; Wei Q; Xu F; Yao H; Zhang Z
    World J Surg Oncol; 2022 Mar; 20(1):93. PubMed ID: 35331250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis.
    Li Y; Du Y; Xue C; Wu P; Du N; Zhu G; Xu H; Zhu Z
    BMC Gastroenterol; 2022 Oct; 22(1):431. PubMed ID: 36217119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
    Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
    Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
    Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
    JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
    Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
    Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer.
    Mazzoli G; Cohen R; Lonardi S; Corti F; Elez E; Fakih M; Jayachandran P; Colle R; Shah AT; Salati M; Fenocchio E; Salvatore L; Ambrosini M; Ros J; Intini R; Cremolini C; Overman MJ; André T; Pietrantonio F
    Eur J Cancer; 2022 Sep; 172():171-181. PubMed ID: 35777274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
    Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
    Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer.
    Yang Z; Wu G; Zhang X; Gao J; Meng C; Liu Y; Wei Q; Sun L; Wei P; Bai Z; Yao H; Zhang Z
    Front Immunol; 2022; 13():1001444. PubMed ID: 36159842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
    Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
    Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients.
    Wu Q; Wang Z; Luo Y; Xie X
    BMC Immunol; 2023 Sep; 24(1):27. PubMed ID: 37658314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
    Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic impact of programmed death - 1 in the treatment of colorectal cancer.
    Sangani PS; Yazdani S; Khalili-Tanha G; Ghorbani E; Al-Hayawi IS; Fiuji H; Khazaei M; Hassanian SM; Kiani M; Ghayour-Mobarhan M; Ferns GA; Nazari E; Avan A
    Pathol Res Pract; 2024 Jul; 259():155345. PubMed ID: 38805760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
    Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
    J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
    Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
    Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies.
    Lin KX; Istl AC; Quan D; Skaro A; Tang E; Zheng X
    Cancer Immunol Immunother; 2023 Dec; 72(12):3875-3893. PubMed ID: 37831146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer.
    André T; Pietrantonio F; Avallone A; Gumus M; Wyrwicz L; Kim JG; Yalcin S; Kwiatkowski M; Lonardi S; Zolnierek J; Odeleye-Ajakaye A; Leconte P; Fogelman D; Kim TW
    Future Oncol; 2023 Dec; 19(37):2445-2452. PubMed ID: 37701986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
    Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M
    Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report.
    Krekeler C; Wethmar K; Mikesch JH; Kerkhoff A; Menck K; Lenz G; Schildhaus HU; Wessolly M; Hoffmann MW; Pascher A; Asmus I; Wardelmann E; Bleckmann A
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.